G&S Research promotes Mike Bandick to SVP

Healthcare marketing research firm G&S Research promoted Mike Bandick to SVP. The move follows a company restructuring that put Bandick at the head of R&S Research's client solutions group.

George Grubb, principal of G&S Research, said in a statement that Bandick's leadership has been “instrumental in navigating the complex opportunities and recent economic contraction of the biopharmaceutical market space that we serve.”

Bandick joined R&S Research in 2006 as VP and business unit leader, and will remain a member of the company's executive committee. Prior to joining R&S Research, Bandick was senior director of marketing for Suros Surgical Systems, which was acquired by Hologic. Before that, Bandick worked in several capacities with Eli Lilly, and was most recently a global marketing director on Cymbalta, Lilly's antidepressant and pain treatment. He also worked on Zyprexa, Lilly's schizophrenia and bipolar drug. 
You must be a registered member of MMM to post a comment.

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters